Q2 2025 Godrej Agrovet Ltd Earnings Call Transcript
Key Points
- Godrej Agrovet Ltd (NSE:GODREJAGRO) reported an improvement in EBITDA margins by 70 bps in Q2 FY 2025, excluding non-recurring items.
- The animal feed segment saw a significant increase in segment margins from 4.6% in Q2 FY 2024 to 5.9% in Q2 FY 2025 due to favorable commodity positions and cost optimization.
- The standalone crop protection segment experienced strong growth with segment margins improving from 30% in Q2 FY 2024 to 43% in Q2 FY 2025.
- The dairy segment demonstrated margin expansion with EBITDA margins improving by 140 bps, driven by operational efficiency gains.
- The company is confident in achieving a 50% growth in the CDMO business over last year, with expectations of reaching INR 400 crores in revenue.
- Astec LifeSciences faced pricing pressures and lower volumes in the CDMO category, adversely affecting revenue and margins.
- The poultry segment recorded a decline in revenue due to lower volumes in the live bird business and an unfavorable channel and product mix.
- The vegetable oil segment revenues were flat due to lower fresh fruit bunch arrivals, despite higher realizations of end products.
- The joint venture in Bangladesh, ACI Godrej, saw a 6% decline in revenues year-on-year due to volume contraction and pricing pressures.
- The fish feed segment experienced a tough time due to erratic rainfall, leading to a degrowth in the first half of the year.
Ladies and gentlemen, good day and welcome to the Godrej Agrovet Ltd earnings call.
(Operator Instructions) Please note that this conference is being recorded. I now hand the conference over to Mr. Probal Sen from ICICI Securities. Thank you and over to you, sir.
Thank you very much. Good afternoon, ladies and gentlemen, thank you so much for making the time for joining us on this Godrej Agrovet Q2 FY 2025 Earnings Conference call. From the company, we have members of the senior management including Mr. Nadir Godrej, the Chairman of the company; Mr. Balram Yadav, the Managing Director; Mr. S. Varadaraj, Chief Financial Officer; And we also have Mr. Arijit Mukherjee, the Chief Operating Officer of Astec LifeSciences, who is joining the call.
We would like to begin the call with a brief opening remarks from the management following which we have a forum open for an interactive Q&A session. Before we start, I would like to point out that some statements made in today's call may be forward
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
